Hennion & Walsh Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-33,663	Closed	-$1.08M	–	907
2024 Q3	$1.08M	Sell	33,663 -3,535	-10%	-$132K	0.05%	437
2024 Q2	$1.4M	Sell	37,198 -314	-0.8%	-$13.2K	0.07%	346
2024 Q1	$1.85M	Buy	37,512 +4,711	+14%	+$218K	0.1%	271
2023 Q4	$1.2M	Sell	32,801 -459	-1%	-$12K	0.07%	364
2023 Q3	$769K	Buy	33,260 +2,400	+8%	+$65.6K	0.05%	419
2023 Q2	$809K	Buy	30,860 +609	+2%	+$16K	0.05%	411
2023 Q1	$779K	Buy	30,251 +5,133	+20%	+$150K	0.05%	410
2022 Q4	$653K	Buy	+25,118	New	+$619K	0.04%	439

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hennion & Walsh Asset Management's SWTX Position: Q4 2024 in Review

Hennion & Walsh Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 33,663 shares — an estimated $1.08M sold.

Hennion & Walsh Asset Management first reported a position in SWTX in Q4 2022 and held it in 8 quarters. The position peaked at $1.85M in Q1 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

Hennion & Walsh Asset Management reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
Hennion & Walsh Asset Management sold 33,663 SpringWorks Therapeutics shares in Q4 2024, an estimated $1.08M.
Hennion & Walsh Asset Management first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 8 quarters.
Hennion & Walsh Asset Management's SpringWorks Therapeutics position peaked at $1.85M in Q1 2024.
216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2024, filed 15 Jan 2025.